You are here: Home ยป Archives for NASDAQ

Zoom unveils AI Companion 3.0 at Zoomtopia 2025, enhancing agentic AI across the Zoom platform

  • Zoom debuts AI Companion 3.0 with agentic AI, delivering powerful new features and work surfaces to transform how teams communicate and collaborate across its platform
  • Zoom Business Services to launch agentic AI features for Customer Experience and Zoom Virtual Agent to redefine customer and employee interactions

SAN JOSE, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) — Today Zoom Communications, Inc. (NASDAQ: ZM) introduced a new era of productivity, intelligent collaboration, and connection, unveiling AI Companion 3.0, with powerful new agentic AI innovations across Zoom Workplace and Zoom Business Services. Announced at Zoomtopia 2025, the company’s annual flagship conference, the innovations showcase Zoom’s vision for agentic AI–first capabilities. Designed to transform how users work, Zoom’s agentic AI turns conversations into action with personalized AI assistance, giving users the power to perform at their best, every day, across multiple surfaces.

“Our customers’ most important conversations happen on Zoom, and now those conversations can result in critical insights to fuel real progress,” said Eric S. Yuan, founder and CEO of Zoom. “With AI Companion 3.0, our agentic AI can understand users’ specific context, priorities, and goals to help them cut through the noise, focus on what matters most, and drive meaningful business outcomes.”

AI Companion 3.0: the ultimate intelligent work companion

Zoom’s vision for the future of work is a unified platform where AI acts as a seamless, intelligent layer. AI Companion 3.0 and the new Zoom Workplace and Business services innovations are at the heart of this vision. More than just an AI assistant, AI Companion works across the Zoom platform and compatible third–party integrations to help users turn conversations into action through deeper conversational insights, save time by tackling administrative tasks, and deliver higher–quality work.

Uncover deeper insights

AI Companion will be able to use agentic AI to retrieve and synthesize internal enterprise knowledge, such as from meeting and phone call transcripts, chat history, and shared documents, with external insights (e.g., publicly available market research and industry data) via unified, context–aware search to deliver critical information at the right time. This will allow users to garner deep insights and receive essential information from their conversations, docs, third–party apps, multiple meeting platforms, in–person meetings, and the web.

With new AI note–taking capabilities, users with paid Zoom Workplace accounts can optimize their manual notes with AI Companion in all of their Zoom meetings, and also for in–person meetings and meetings that take place outside of Zoom, such as on Microsoft Teams, Google Meet, and WebEx (coming soon).

Optimize the workday
Proactive agentic skills can help manage busywork so users can focus on what matters. New capabilities, such as “free up my time,” meeting preparation, group assistance, and in–meeting recommendations, help users stay informed by offering the right information at the right time so they can complete their tasks with less effort.

AI Companion, with its new, outcome–focused prompts, will help drive results by helping users identify, prioritize, and complete tasks across the Zoom platform — including meetings, phone calls, chats, and emails — so nothing falls through the cracks.

Deliver high–quality work faster

Users can interact with AI Companion as a collaboration partner to uplevel their work with less guidance because it already understands their context. It knows their most recent and frequent conversation topics and important projects, providing suggested actions and tailored responses to help them deliver the best possible outputs.

AI Companion 3.0 introduces a new work surface in web browsers and the Zoom Workplace desktop app to deliver a single coherent AI experience regardless of where users are working. The work surface dynamically adapts and offers a full breadth of context, turning scattered information into actionable intelligence.

With new writing assistance and deep research skills, users can generate comprehensive, data–driven reports and polished documents using internal and external data sources.

Advanced AI platform innovations

Zoom is pushing the boundaries of communication with new AI and platform features for Zoom Workplace, including new lifelike meeting avatars, the ability to generate clips from presentations, and support for Model Context Protocol (MCP) that will allow customers and developers to configure tools for customer and virtual agents.

The addition of real–time voice translation for Zoom Meetings helps Zoom users collaborate more easily with global colleagues and partners with the Zoom quality that organizations know and love. This is supported by a recent evaluation commissioned by Zoom in which Zoom’s real–time translated captions solution was found to deliver greater accuracy than leading competitors using MetricX standard: 28% more accurate for English–to–French translations and 14% more accurate for English–to–Spanish translations.

Customized solutions

For organizations that need agentic AI that is more tailored to their business needs, Custom AI Companion now offers the ability to create and deploy custom AI agents. Available beginning today, this low–code builder empowers admins to create and deploy tailored AI solutions directly to their employees, with access to a comprehensive, rich tooling library and pre–built templates for various workflows. Additionally, admins can connect to pre–built, third–party agents and use the Agent2Agent (A2A) protocol to get work done across applications.

AI Companion 3.0 capabilities are expected to be generally available in November 2025, at no additional cost with the paid services in Zoom Workplace accounts. The Custom AI Companion add–on is available for $12 per user, per month.

Visit the Zoom newsroom for more information on the latest innovations that enhance collaboration and productivity across Zoom Workplace.

Zoom Business Services supercharges customer and employee experiences

Zoom’s commitment to businesses extends beyond collaboration, with new innovations in its Customer Experience (CX) suite and Zoom Virtual Agent (ZVA), including AI–first features designed to enhance agent performance, improve customer experience, and provide actionable insights for leaders.

Zoom customer experience innovations announced at Zoomtopia include the ability to automate support agent tasks with Agentic AI Expert Assist, uncover business intelligence from customer data with CX Insights, and extend quality oversight to virtual agent interactions with Automated Quality Management. Additionally, Zoom is introducing a “bring your own voice” capability to ZVA, allowing companies to create a more consistent and on–brand conversational experience.

Zoom is bringing the power of agentic AI beyond customer support and into the earliest stages of the customer journey. With Zoom Revenue Accelerator (ZRA), sales teams gain AI–driven capabilities that take on the heavy lifting of prospecting, follow–up, and scheduling. ZRA’s new agentic prospecting skill scans event lists and other lead sources, intelligently identifies high–potential prospects, initiates personalized outreach across channels like email and SMS, and even schedules initial touchpoints.

Visit the Zoom newsroom for more information on the latest innovations for Zoom Business Services.

Watch Zoomtopia Live

Tune in to Zoomtopia today for the Americas and tomorrow, September 18, for APAC, EMEA, and Japan to learn more about these innovations. Unless otherwise noted, these innovations will be available to Zoom customers on September 17, 2025. For more information about these announcements and Zoom’s new AI for Good program, visit the Zoom newsroom.

About Zoom
Zoom’s mission is to provide an AI–first work platform for human connection. Reimagine teamwork with Zoom Workplace — Zoom’s open collaboration platform with AI Companion that empowers teams to be more productive. Together with Zoom Workplace, Zoom’s Business Services for sales, marketing, and customer experience teams, including Zoom Contact Center, strengthen customer relationships throughout the customer lifecycle. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and headquartered in San Jose, California. Get more information at zoom.com.

The statements contained here are for informational purposes only and may not be incorporated into any contract. Any services, products, or functionality referenced that are not currently available are subject to change at Zoom’s sole discretion and may not be delivered as planned or at all. Customers who purchase from Zoom should make their purchase decisions based on currently available pricing, features, and functions.

Zoom Public Relations
Travis Isaman
[email protected]


GLOBENEWSWIRE (Distribution ID 9530699)

Nyxoah Entame une Procédure Judiciaire pour Violation de Brevets Contre Inspire Medical Systems, Inc.

Nyxoah Entame une Procédure Judiciaire pour Violation de Brevets Contre Inspire Medical Systems, Inc.

Mont–Saint–Guibert, Belgique – 15 septembre 2025, 22h10 CET / 16h10 ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (« Nyxoah » ou la « Société »), une société de technologie médicale développant des alternatives thérapeutiques révolutionnaires pour l'apnée obstructive du sommeil (AOS) par la neuromodulation, a annoncé aujourd'hui avoir entamé une procédure judiciaire contre Inspire Medical Systems, Inc. (« Inspire ») en alléguant que les dispositifs Inspire IV et Inspire V enfreignent les trois brevets suivants détenus par la Société : brevets américains n° 8 700 183, 9 415 215 et 9 415 216. La plainte a été déposée devant le tribunal fédéral de première instance du district du Delaware, afin d'obtenir une mesure injonctive et des dommages–intérêts pour contrefaçon.

“Nous défendrons notre portefeuille de propriété intellectuelle et le système Genio® exclusif et mini–invasif, qui ne repose pas sur le matériel traditionnel des stimulateurs cardiaques, mais constitue une solution différenciée offrant une stimulation bilatérale, une compatibilité IRM pour tout le corps et une plateforme technologique évolutive qui ne nécessite pas de nouvelle intervention chirurgicale pour le remplacement des batteries”, a déclaré Olivier Taelman, Chief Executive Officer. “Chez Nyxoah, nous restons déterminés à donner la priorité aux patients et à offrir aux médecins une alternative, en leur faisant confiance pour prendre la meilleure décision pour leurs patients souffrant d'AOS. Nous sommes ravis des commentaires positifs que nous avons reçus de la part des médecins et des patients au cours du premier mois suivant le lancement commercial aux États–Unis et nous sommes impatients de présenter le système Genio à davantage de médecins et de patients atteints d'AOS afin qu'ils puissent choisir la solution la mieux adaptée à leurs besoins.”

A propos de Nyxoah

Nyxoah opère dans le secteur des technologies médicales. Elle se concentre sur le développement et la commercialisation de solutions innovantes destinées à traiter le Syndrome d’Apnées Obstructives du Sommeil (SAOS). La principale solution de Nyxoah est le système Genio®, une thérapie de neurostimulation du nerf hypoglosse sans sonde et sans batterie qui a reçu le marquage CE, centrée sur le patient et destinée à traiter le Syndrome d’Apnées Obstructives du Sommeil (SAOS), le trouble respiratoire du sommeil le plus courant au monde. Ce dernier est associé à un risque accru de mortalité et des comorbidités, dont les maladies cardiovasculaires. La vision de Nyxoah est que les patients souffrant de SAOS doivent pouvoir profiter de nuits réparatrices et vivre pleinement leur vie.

À la suite de la finalisation probante de l’étude BLAST OSA, le système Genio® a reçu le marquage européen CE en 2019. Nyxoah a réalisé avec succès deux IPO : l’une sur Euronext Bruxelles en septembre 2020 et l’autre sur le NASDAQ en juillet 2021. Grâce aux résultats positifs de l'étude BETTER SLEEP, Nyxoah a reçu le marquage CE pour l’extension de ses indications thérapeutiques aux patients souffrant de collapsus concentrique complet (CCC), pour lesquels les thérapies concurrentes sont actuellement contre–indiquées. En outre, la Société a annoncé les résultats positifs de l'étude pivot DREAM IDE et l'approbation par la FDA américaine d'une demande d'autorisation préalable à la mise sur le marché.

Pour plus d’informations, visitez www.nyxoah.com

Attention – Marquage CE depuis 2019. Dispositif de recherche aux États–Unis. Approuvé par la FDA en août 2025 en tant que dispositif disponible uniquement sur prescription médicale.

Déclarations Prospectives

Certaines déclarations, convictions et opinions contenues dans ce communiqué de presse sont de nature prospective et reflètent les attentes actuelles de la Société ou, le cas échéant, de ses administrateurs ou de sa direction concernant le système Genio ; les études cliniques prévues et en cours sur le système Genio ; les avantages potentiels du système Genio ; les objectifs de Nyxoah en matière de développement, de parcours réglementaire et d'utilisation potentielle du système Genio ; la stratégie de commercialisation de la société et son entrée sur le marché américain ; et les résultats d'exploitation, la situation financière, la liquidité, les performances, les perspectives, la croissance et les stratégies de la société. De par leur nature, les déclarations prospectives comportent un certain nombre de risques, d'incertitudes, d'hypothèses et d'autres facteurs qui pourraient faire en sorte que les résultats ou événements réels diffèrent sensiblement de ceux exprimés ou sous–entendus dans les déclarations prospectives. Ces risques, incertitudes, hypothèses et facteurs pourraient avoir une incidence défavorable sur les résultats et les effets financiers des plans et événements décrits dans le présent document. En outre, ces risques et incertitudes comprennent, sans s'y limiter, les risques et incertitudes énoncés dans la section « Facteurs de risque » du rapport annuel de la société sur le formulaire 20–F pour l'exercice clos le 31 décembre 2024, déposé auprès de la Securities and Exchange Commission (« SEC ») le 20 mars 2025, et dans les rapports ultérieurs que la Société dépose auprès de la SEC. Une multitude de facteurs, y compris, mais sans s'y limiter, les changements dans la demande, la concurrence et la technologie, peuvent faire en sorte que les événements, les performances ou les résultats réels diffèrent considérablement de toute évolution prévue. Les déclarations prospectives contenues dans le présent communiqué de presse concernant les tendances ou activités passées ne constituent pas des garanties de performances futures et ne doivent pas être interprétées comme une indication que ces tendances ou activités se poursuivront à l'avenir. En outre, même si les résultats ou développements réels sont conformes aux déclarations prospectives contenues dans le présent communiqué de presse, ces résultats ou développements ne sont pas nécessairement indicatifs des résultats ou développements futurs. Aucune déclaration ni garantie n'est faite quant à l'exactitude ou à l'équité de ces déclarations prospectives. Par conséquent, la Société décline expressément toute obligation ou engagement de publier des mises à jour ou des révisions des déclarations prospectives contenues dans le présent communiqué de presse à la suite d'un changement dans les attentes ou d'un changement dans les événements, les conditions, les hypothèses ou les circonstances sur lesquels ces déclarations prospectives sont fondées, sauf si la loi ou la réglementation l'exige expressément. Ni la Société, ni ses conseillers ou représentants, ni aucune de ses filiales, ni aucun des dirigeants ou employés de ces personnes ne garantissent que les hypothèses sous–jacentes à ces déclarations prospectives sont exemptes d'erreurs, et n'acceptent aucune responsabilité quant à l'exactitude future des déclarations prospectives contenues dans le présent communiqué de presse ou à la réalisation effective des développements prévus. Vous ne devez pas vous fier indûment aux déclarations prospectives, qui ne sont valables qu'à la date du présent communiqué de presse.

Contacts :

Nyxoah
John Landry, CFO
[email protected]

Pièce jointe


GLOBENEWSWIRE (Distribution ID 1001128138)

Nyxoah Files Patent Infringement Lawsuit Against Inspire Medical Systems, Inc.

Nyxoah Files Patent Infringement Lawsuit Against Inspire Medical Systems, Inc.

Mont–Saint–Guibert, Belgium – September 15, 2025, 10:10pm CET / 4:10pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) and Nyxoah, Inc. (collectively, “Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced that it has filed a lawsuit against Inspire Medical Systems, Inc. (“Inspire”) alleging that the Inspire IV and Inspire V devices infringe the following three patents held by the Company; U.S. Patent Nos. 8,700,183, 9,415,215, and 9,415,216. The suit was filed in the United States District Court for the District of Delaware, seeking injunctive relief and damages for infringement.

“We will defend our intellectual property portfolio and the proprietary, minimally invasive Genio® system, which does not rely on traditional pacemaker hardware but is a differentiated solution offering bi–lateral stimulation, full body MRI compatibility and an upgradable technology platform that does not require re–surgery for battery replacements,” said Olivier Taelman, Chief Executive Officer. “At Nyxoah, we remain committed to putting patients first and offering physicians an alternative, trusting them to make the best decision for their patients suffering from OSA. We’re excited about the positive feedback we have received from both physicians and patients in the first month post–US commercial launch and look forward to introducing the Genio system to more physicians and OSA patients so they can choose the best solution for their needs.”

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient–centered, leadless and battery–free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and U.S. FDA approval of a Premarket Approval application.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. FDA approved in August 2025 as prescription–only device.

FORWARD–LOOKING STATEMENTS

Certain statements, beliefs and opinions in this press release are forward–looking, which reflect the Company’s or, as appropriate, the Company directors’ or managements’ current expectations regarding the Genio system; planned and ongoing clinical studies of the Genio system; the potential advantages of the Genio system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio system; the Company's commercialization strategy and entrance to the U.S. market; the Company’s intellectual property portfolio; and the Company's results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward–looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward–looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20–F for the year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2025, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, or adverse litigation outcomes can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward–looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward–looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward–looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward–looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward–looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward–looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward–looking statements, which speak only as of the date of this press release.

Contacts:

Nyxoah
John Landry, CFO
[email protected]

Attachment


GLOBENEWSWIRE (Distribution ID 1001128138)

Zoom recognized in the 2025 Gartner® Magic Quadrant™ for Contact Center as a Service for the first time

SAN JOSE, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) — Zoom Communications, Inc. (NASDAQ: ZM) today announced it has been recognized in the 2025 Gartner® Magic Quadrant™ for Contact Center as a Service (CCaaS). This is Zoom’s first inclusion in the Magic Quadrant for CCaaS, just three years after launching Zoom Contact Center in 2022.

Zoom believes this recognition highlights the strength of Zoom’s AI–first approach to customer experience, where AI is embedded in the platform from the ground up to support both self–service automation and live agent assistance.

“To us, being recognized in the Gartner Magic Quadrant™ for CCaaS so soon after launching Zoom Contact Center is an incredible milestone,” said Chris Morrissey, general manager of Zoom CX. “We believe this validates our AI–first platform strategy and underscores our commitment to helping organizations move faster, operate smarter, and transform customer experience in a meaningful, differentiated way.”

Zoom’s recognition in the CCaaS Magic Quadrant follows its presence in the Gartner Magic Quadrant for UCaaS. Zoom believes this reflects the strength of Zoom’s unified platform strategy, delivering both communication and contact center capabilities within a single, easy–to–use experience.

Download a complimentary copy of the Gartner Magic Quadrant for CCaaS here to read the full report.

To learn more about Zoom Contact Center, visit the Zoom website.

Gartner Disclaimer
Gartner, Magic Quadrant for Contact Center as a Service, Drew Kraus, Jason Bridge, Megan Marek Fernandez, Pri Rathnayake, Pankil Sheth, September 10th, 2025.

Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

GARTNER is a registered trademark and service mark, and MAGIC QUADRANT is a registered trademark of Gartner, Inc. and/or its affiliates, and are used herein with permission. All rights reserved.

About Zoom
Zoom’s mission is to provide an AI–first work platform for human connection. Reimagine teamwork with Zoom Workplace — Zoom’s open collaboration platform with AI Companion that empowers teams to be more productive. Together with Zoom Workplace, Zoom’s Business Services for sales, marketing, and customer experience teams, including Zoom Contact Center, strengthen customer relationships throughout the customer lifecycle. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and headquartered in San Jose, California. Get more information at zoom.com.

Zoom Public Relations
Travis Isaman
[email protected]


GLOBENEWSWIRE (Distribution ID 9526834)

Vimeo Enters into Definitive Agreement to Be Acquired by Bending Spoons for $1.38 Billion

Vimeo stockholders to receive $7.85 per share in cash
Bending Spoons reinforces its commitment to innovation in the video platform market

NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) — Vimeo, Inc. (NASDAQ: VMEO), a leading video platform for business, today announced that it has entered into a definitive agreement to be acquired by Bending Spoons, in an all–cash transaction valued at approximately $1.38 billion. Under the terms of the agreement, Vimeo shareholders will receive $7.85 per share in cash for each share of Vimeo capital stock that they own. The per–share purchase price represents a 91% premium over Vimeo’s 60–day volume–weighted average share price as of market close on September 9, 2025.

“After a disciplined review of strategic alternatives, the Board unanimously determined that this all–cash transaction delivers compelling, certain value to Vimeo shareholders and positions the company to accelerate its strategic roadmap as part of Bending Spoons,” said Glenn H. Schiffman, Chairman of the Board. “We’re confident they are the right long–term partner for our customers, employees, and brand.”

“Bending Spoons has tremendous respect for the Vimeo team, our customers and the creator community we serve,” said Philip Moyer, Vimeo CEO. “Luca and his team are committed to expanding our product across all segments: Self–Serve, OTT/Vimeo Streaming, and Vimeo Enterprise. We are excited about this partnership, which we believe will unlock even greater focus for our team and customers as we continue to strive towards our global mission to be the most innovative and trusted video platform in the world for businesses.”

“We’re looking forward to welcoming Vimeo into the Bending Spoons portfolio,” said Luca Ferrari, Bending Spoons CEO and co–founder. “Vimeo is a pioneering brand in the video space, serving a passionate, global community of creators and businesses. At Bending Spoons, we acquire companies with the expectation of owning and operating them indefinitely, and we look forward to realizing Vimeo’s full potential as we reach new heights together. In particular, after closing, we’re determined to make ambitious investments in the US and other priority markets, and all key areas of the business, spanning both the creator and enterprise offerings. We'll focus on achieving even more stellar levels of performance and reliability, bringing advanced features to more customers, and continuing to release powerful and responsible AI–enabled features.””

Details of the Transaction
The transaction, which was unanimously approved by Vimeo’s Board of Directors, is expected to close in the fourth quarter of 2025, subject to customary closing conditions and approvals, including approval by Vimeo’s stockholders, and the receipt of required regulatory approvals.

Upon the completion of the transaction, Vimeo will become a privately held company and its capital stock will no longer be listed on any public stock exchange.

Financial Reporting Update
Vimeo does not currently expect to hold an earnings call for the third quarter of 2025. The Company expects to release written third–quarter earnings results for the third quarter of 2025 in accordance with SEC rules, and to continue meeting its applicable reporting obligations during the pre–close period.

Advisors
Skadden, Arps, Slate, Meagher & Flom LLP are serving as legal advisors to Vimeo, and Allen & Company LLC as financial advisors.

Latham & Watkins LLP is serving as legal advisor to Bending Spoons. J.P. Morgan and Wells Fargo acted as joint lead financial advisors and BNP acted as financial advisor. EY Advisory SpA and EY SLT provided financial and tax due diligence services.

About Vimeo
Vimeo (NASDAQ: VMEO) is one of the world's most innovative video experience platforms. We enable anyone to create high–quality video experiences to better connect and bring ideas to life. We proudly serve our community of millions of users – from creative storytellers to globally distributed teams at the world's largest companies – whose videos receive billions of views each month. Learn more at https://www.vimeo.com.

About Bending Spoons
Bending Spoons has served a billion people across the globe through its suite of digital technology businesses, including Brightcove, Evernote, Meetup, komoot, Remini, and WeTransfer. Its products are currently used by more than 300 million people and 10 million paying customers each month.

For more information, visit bendingspoons.com.
Bending Spoons logos and photos: https://we.tl/t–NXGPsC6Gtn.

Additional Information and Where to Find It

In connection with the proposed transaction by and among Vimeo, Inc. (the “Company”), Bending Spoons US Inc. (“Parent”), Bloomberg Merger Sub Inc. (“Merger Sub”) and Bending Spoons S.P.A. (“Guarantor”), the Company expects to seek, and intends to file with the Securities and Exchange Commission (“SEC”) a proxy statement on Schedule 14A (the “Proxy Statement”), the definitive version of which will be sent or provided to Company stockholders, in connection with a special meeting of the Company’s stockholders for purposes of obtaining, stockholder approval of the proposed transaction. The Company may also file other documents with the SEC regarding the proposed transaction. This document is not a substitute for the Proxy Statement or any other document which the Company may file with the SEC. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS AND DOCUMENTS INCORPORATED BY REFERENCE.

THEREIN, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND RELATED MATTERS. Investors and security holders may obtain free copies of the Proxy Statement (when it is available) and other documents that are filed or will be filed with the SEC by the Company through the website maintained by the SEC at www.sec.gov, the Company’s investor relations website at investors.vimeo.com or by contacting the Company’s investor relations department at [email protected].

Participants in the Solicitation

The Company and certain of its directors, executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies from the Company’s stockholders in respect of the proposed transaction and any other matters to be voted on at the special meeting. Information regarding the Company’s directors and executive officers, including a description of their direct interests, by security holdings or otherwise, is contained in the Company’s proxy statement for its 2025 annual meeting of stockholders, which was filed with the SEC on April 29, 2025, the Company’s Annual Report on Form 10–K for the fiscal year ended December 31, 2024, which was filed with the SEC on February 19, 2025, and in subsequently filed Current Reports on Form 8–K and Quarterly Reports on Form 10–Q, and will be included in the Proxy Statement (when available). Company stockholders may obtain additional information regarding the direct and indirect interests of the participants in the solicitation of proxies in connection with the proposed transaction, including the interests of Company directors and executive officers in the proposed transaction, which may be different than those of Company stockholders generally, by reading the Proxy Statement and any other relevant documents that are filed or will be filed with the SEC relating to the proposed transaction. You may obtain free copies of these documents using the sources indicated above.

Cautionary Statement Regarding Forward–Looking Statements

This communication contains “forward–looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act. These forward–looking statements are based on the Company’s current expectations, estimates and projections about the expected date of closing of the proposed transaction and the potential benefits thereof, its business and industry, management’s beliefs and certain assumptions made by the Company, Parent, Merger Sub and Guarantor, all of which are subject to change. In this context, forward–looking statements often address expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “could,” “seek,” “see,” “will,” “may,” “would,” “might,” “potentially,” “estimate,” “continue,” similar expressions or the negatives of these words or other comparable terminology that convey uncertainty of future events or outcomes. All forward–looking statements by their nature address matters that involve risks and uncertainties, many of which are beyond our control, and are not guarantees of future results, such as statements about the consummation of the proposed transaction and the anticipated benefits thereof. These and other forward–looking statements, including the failure to consummate the proposed transaction or to make or take any filing or other action required to consummate the proposed transaction on a timely matter or at all, are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed in any forward–looking statements. Accordingly, there are or will be important factors that could cause actual results to differ materially from those indicated in such statements and, therefore, you should not place undue reliance on any such statements and caution must be exercised in relying on forward–looking statements. Important risk factors that may cause such a difference include, but are not limited to: (i) the ability of the parties to consummate the proposed transaction in the anticipated time period or at all; (ii) the satisfaction (or waiver) of closing conditions to the consummation of the proposed transaction, including the receipt of required regulatory approval and the requisite approval of the Company’s stockholders; (iii) potential delays in consummation of the proposed transaction; (iv) risks associated with the disruption of management’s attention from ongoing business operations due to the pendency and announcement of the proposed transaction; (v) the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the merger agreement; (vi) the Company’s ability to implement its business strategy; (vii) significant transaction costs associated with the proposed transaction; (viii) the risk that Company’s stock price may decline significantly if the proposed transaction is not consummated; (ix) the nature, cost and outcome of any potential litigation relating to the proposed transaction; (x) the risk that disruptions from the proposed transaction will harm the Company’s business, including current plans and operations; (xi) the effects of the proposed transaction on relationships with employees, other business partners or governmental entities; (xii) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed transaction; (xiii) legislative, regulatory and economic developments affecting the Company’s business; (xiv) general economic and market developments and conditions; (xv) the evolving legal, regulatory and tax regimes under which the Company operates; (xvi) potential business uncertainty, including changes to existing business relationships, during the pendency of the merger that could affect the Company’s financial performance; (xvii) restrictions during the pendency of the proposed transaction that may impact the Company’s ability to pursue certain business opportunities or strategic transactions; and (xviii) unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism or outbreak of war or hostilities, as well as the Company’s response to any of the aforementioned factors. These risks, as well as other risks associated with the proposed transaction, will be more fully discussed in the Proxy Statement to be filed with the SEC in connection with the proposed transaction. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward–looking statements are included under the caption “Risk Factors” in the Company’s most recent annual and quarterly reports filed with the SEC and any subsequent reports on Form 10–K, Form 10–Q or Form 8–K filed from time to time and available at www.sec.gov. While the list of factors presented here is, and the list of factors presented in the Proxy Statement will be, considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward–looking statements. Consequences of material differences in results as compared with those anticipated in the forward–looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability and similar risks, any of which could have a material adverse effect on the Company’s financial condition, results of operations, or liquidity. The forward–looking statements included herein are made only as of the date hereof. The Company does not assume any obligation to publicly provide revisions or updates to any forward–looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.


GLOBENEWSWIRE (Distribution ID 9526710)

Entera Bio Presents Positive Effects of EB613 on Both Trabecular and Cortical Bone in Postmenopausal Women with Osteoporosis at ASBMR 2025

EB613 Demonstrates Significant Effects on Both Trabecular and Cortical Bone Compartments After Just 6 Months of Treatment in Phase 2 Study; Cortical Improvements Comparable to Injectable Teriparatide and Abaloparatide

Company Plans to Initiate Global Registrational Phase 3 Study Following July 2025 FDA Concurrence

Entera also Presented Promising Pharmacokinetic Data for Next–Gen EB613 Single Tablet Candidate as Potential Future Franchise Extension

JERUSALEM, Sept. 08, 2025 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, today announced data selected for presentation at the American Society for Bone and Mineral Research (“ASBMR”) 2025 Annual Meeting in Seattle, Washington, for its lead program EB613 which is in late stage clinical development for post–menopausal women with osteoporosis. It is estimated that 50 percent of women and 20 percent of men over the age of 50 are at risk of a fragility fractures and less than 30% of patients are adequately treated with available medications.

“The data presented at ASBMR this year marks important progress for our EB613 program,” said Miranda Toledano, Chief Executive Officer of Entera. “Available injectable anabolic treatments, while efficacious and recommended across medical guidelines, are only accessible to a minority of patients globally. Our EB613 program is being developed to address the treatment chasm in osteoporosis care with a viable anabolic treatment in tablet format for patients to adequately protect their bones.”

In the oral presentation titled “Effects of EB613 Tablets [Oral PTH(1–34)] on Trabecular and Cortical Bone Using 3D–DXA: Results from Phase 2 Study,” Rachel B. Wagman, MD presented data using 3D–DXA modelling in a post–hoc analysis of EB613 Phase 2 results to look at the treatment’s impact on trabecular and cortical bone. After 6 months of treatment, EB613 2.5 mg demonstrated significant increases in both trabecular and cortical bone parameters as compared with placebo. Mechanistically, the findings suggest that bone strengthening, and fracture resistance may occur rapidly with EB613.

“The improvements across multiple parameters, including integral volumetric BMD, cortical thickness, and cortical surface BMD, suggest that there is an early strengthening effect with EB613 and a deterioration with placebo,” said Dr. Wagman. “We look forward to studying the safety and efficacy of EB613 in Phase 3.”

  • Increases in integral volumetric BMD of the TH and FN by 1.7% (p<0.08) and 2.6% (p<0.03), respectively
  • Increases in FN trabecular volumetric BMD by 4.4% vs. placebo (p<0.03) and increases in TH trabecular volumetric BMD by 2.8% (p=0.05 vs. baseline, NS compared with placebo)
  • Increases in cortical thickness at the TH and FN by 1.3% (p=0.04) and 1.7% (p=0.056), respectively Improvements in cortical surface BMD at the TH and FN by 1.5% and 2.1%, respectively (both p<0.05)

In a poster presentation titled “Advancing Oral Anabolic Treatments for Osteoporosis: Pre–Clinical Data for Next–Gen EB613 Tablet Utilizing N–Tab™ Proprietary Technology,” Entera presented preclinical data for its Next–Gen EB613 candidate. In a cross–over pharmacokinetic study in minipigs, a single 1.5 mg Next–Gen EB613 tablet demonstrated comparable PK to the current formulation of EB613, with identical AUClast and Tmax values (1.2 min*ng/ml and 20 min, respectively), and comparable Cmax. A Phase 1 clinical trial of Next–Gen EB613 is planned to begin in late 2025.

About EB613

Substantial evidence supports the efficacy of anabolic treatments over anti–resorptive drugs for lowering fracture risk in osteoporosis patients. However, all available anabolic therapies are administered by subcutaneous (SC) injection and used in a minority of eligible patients. EB613 (oral PTH (1–34)), is being developed as the first oral, once–daily anabolic tablet treatment for osteoporosis. EB613 completed a phase 2, 6–month, 161–patient, placebo–controlled study that met all biomarker and BMD endpoints without significant safety concerns in women with postmenopausal osteoporosis or low BMD (JBMR 2024). EB613 produced rapid dose–proportional increases in biochemical markers of bone formation, reductions in markers of bone resorption, and increased lumbar spine, total hip, and femoral neck BMD.

About Entera Bio

Entera is a clinical stage company focused on developing oral peptide and protein replacement therapies for significant unmet medical needs where an oral tablet form holds the potential to transform the standard of care. The Company leverages on a disruptive and proprietary technology platform (N–Tab™) and its pipeline of first–in–class oral peptide programs targeting PTH(1–34), GLP–1 and GLP–2. The Company’s most advanced product candidate, EB613 (oral PTH(1–34), teriparatide), is being developed as the first oral, osteoanabolic (bone building) once–daily tablet treatment for post–menopausal women with low BMD and high–risk osteoporosis. A placebo–controlled, dose–ranging Phase 2 study of EB613 tablets (n= 161) met primary (PD/bone turnover biomarker) and secondary endpoints (BMD). The EB612 program is being developed as the first oral PTH(1–34) tablet peptide replacement therapy for hypoparathyroidism. Entera is also developing the first oral oxyntomodulin, a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity and metabolic syndromes; and first oral GLP–2 peptide as an injection–free alternative for patients suffering from rare malabsorption conditions such as short bowel syndrome in collaboration with OPKO Health. For more information on Entera Bio, visit www.enterabio.com or follow us on LinkedIn, Twitter, and Facebook.

Cautionary Statement Regarding Forward Looking Statements

Various statements in this press release are “forward–looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements (other than statements of historical facts) in this press release regarding our prospects, plans, financial position, business strategy and expected financial and operational results may constitute forward–looking statements. Words such as, but not limited to, “anticipate,” “believe,” “can,” “could,” “expect,” “estimate,” “design,” “goal,” “intend,” “may,” “might,” “objective,” “plan,” “predict,” “project,” “target,” “likely,” “should,” “will,” and “would,” or the negative of these terms and similar expressions or words, identify forward–looking statements. Forward–looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Forward–looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Important factors that could cause actual results to differ materially from those reflected in Entera's forward–looking statements include, among others: changes in the interpretation of clinical data; results of our clinical trials; the FDA's interpretation and review of our results from and analysis of our clinical trials; unexpected changes in our ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates; the potential disruption and delay of manufacturing supply chains; loss of available workforce resources, either by Entera or its collaboration and laboratory partners; impacts to research and development or clinical activities that Entera may be contractually obligated to provide; overall regulatory timelines; the size and growth of the potential markets for our product candidates; the scope, progress and costs of developing Entera's product candidates; Entera's reliance on third parties to conduct its clinical trials; Entera's ability to establish and maintain development and commercialization collaborations; Entera's operation as a development stage company with limited operating history; Entera's competitive position with respect to other products on the market or in development for the treatment of osteoporosis, hypoparathyroidism, short bowel syndrome, obesity, metabolic conditions and other disease categories it pursues; Entera's ability to continue as a going concern absent access to sources of liquidity; Entera's ability to obtain and maintain regulatory approval for any of its product candidates; Entera's ability to comply with Nasdaq's minimum listing standards and other matters related to compliance with the requirements of being a public company in the United States; Entera's intellectual property position and its ability to protect its intellectual property; and other factors that are described in the “Cautionary Statement Regarding Forward–Looking Statements,” “Risk Factors” and “Management's Discussion and Analysis of Financial Condition and Results of Operations” sections of Entera's most recent Annual Report on Form 10–K filed with the SEC, as well as Entera's subsequently filed Quarterly Reports on Form 10–Q and Current Reports on Form 8–K. There can be no assurance that the actual results or developments anticipated by Entera will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Entera. Therefore, no assurance can be given that the outcomes stated or implied in such forward–looking statements and estimates will be achieved. Entera cautions investors not to rely on the forward–looking statements Entera makes in this press release. The information in this press release is provided only as of the date of this press release, and Entera undertakes no obligation to update or revise publicly any forward–looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law.


GLOBENEWSWIRE (Distribution ID 9524990)

Publication relating to transparency notifications

                

REGULATED INFORMATION

Publication relating to transparency notifications

Mont–Saint–Guibert (Belgium), September 5, 2025, 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below.

On September 4, 2025, Nyxoah received a transparency notification from Cochlear Limited and Cochlear Investments Pty Ltd following a passive crossing of a threshold. Based on the notification, Cochlear Investments Pty Ltd holds 5,631,319 voting rights, representing 14.999% of the total number of voting rights on August 29, 2025 (37,544,782).

The notification dated September 4, 2025 contains the following information:

  • Reason for the notification: passive crossing of a threshold
  • Notification by: a parent undertaking or a controlling person
  • Persons subject to the notification requirement:
    • Cochlear Limited (with address at 1 University Avenue, Macquarie University, NSW 2109, Australia)
    • Cochlear Investments Pty Ltd (with address at 1 University Avenue, Macquarie University, NSW 2109, Australia)
  • Date on which the threshold was crossed: August 29, 2025
  • Threshold that is crossed: 15%
  • Denominator: 37,544,782
  • Notified details:
A) Voting rights Previous notification After the transaction
  # of voting rights # of voting rights % of voting rights
Holders of voting rights   Linked to securities Not linked to the securities Linked to securities Not linked to the securities
Cochlear Limited 0 0 0 0.00% 0.00%
Cochlear Investments Pty Ltd 3,947,617 5,631,319 0 15.00% 0.00%
Subtotal 3,947,617 5,631,319   15.00%  
  TOTAL 5,631,319 0 15.00% 0.00%
  • Full chain of controlled undertakings through which the holding is effectively held: Cochlear Investments Pty Ltd is a wholly owned subsidiary of Cochlear Limited, which is listed on the Australian Securities Exchange and has no controlling shareholder.
  • Additional information: This notification concerns a downward crossing of the 15% threshold following a passive decrease, whereby Cochlear Investments Pty Ltd’s holding in Nyxoah fell from 15.04% to 14.999% of the voting rights.

*

* *

Contact:
Nyxoah
John Landry, CFO
[email protected]

Attachment


GLOBENEWSWIRE (Distribution ID 1001126581)

Publication relative à des notifications de transparence

        

INFORMATION RÉGLEMENTÉE

Publication relative à des notifications de transparence

Mont–Saint–Guibert (Belgique), le 5 septembre 2025, 22:30h CET / 16:30h ET – Conformément à l'article 14 de la loi du 2 mai 2007 relative à la publicité des participations importantes, Nyxoah SA (Euronext Brussels/Nasdaq : NYXH) annonce qu’elle a reçu une notification de transparence comme détaillée ci–dessous.

Le 4 septembre 2025, Nyxoah a reçu une notification de transparence de Cochlear Limited et Cochlear Investments Pty Ltd suite à un franchissement de seuil passif. Sur la base de la notification, Cochlear Investments Pty Ltd détient 5.631.319 droits de vote, représentant 14,999% du nombre total des droits de vote en date du 29 aout 2025 (37.544.782).

La notification datée du 4 septembre 2025 contient les informations suivantes :

  • Motif de la notification : franchissement de seuil passif
  • Notification par : une entreprise mère ou une personne détenant le contrôle
  • Personnes tenues à la notification :
    • Cochlear Limited (avec adresse à 1 University Avenue, Macquarie University, NSW 2109, Australie)
    • Cochlear Investments Pty Ltd (avec adresse à 1 University Avenue, Macquarie University, NSW 2109, Australie)
  • Date du dépassement de seuil : le 29 aout 2025
  • Seuil franchi : 15%
  • Dénominateur : 37.544.782
  • Détails de la notification :
A) Droits de vote Notification précédente Après la transaction
  # droits de vote # droits de vote % de droits de vote
Détenteurs de droits de vote   Attachés à des titres Non liés à des titres Attachés à des titres Non liés à des titres
Cochlear Limited 0 0 0 0,00% 0,00%
Cochlear Investments Pty Ltd 3.947.617 5,631,319 0 15,00% 0,00%
Sous–total 3.947.617 5,631,319   15,00%  
  TOTAL 5,631,319 0 15,00% 0,00%
  • Chaine des entreprises contrôlées par l'intermédiaire desquelles la participation est effectivement détenue : Cochlear Investments Pty Ltd est une filiale à 100 % de Cochlear Limited, société cotée à l’Australian Securities Exchange et sans actionnaire de contrôle.
  • Information supplémentaire : Cette notification concerne le franchissement à la baisse du seuil de 15 % à la suite d'une diminution passive, la participation de Cochlear Investments Pty Ltd dans Nyxoah étant passée de 15,04 % à 14,999 % des droits de vote.

*

* *

Contact:
Nyxoah
John Landry, CFO
[email protected]

Pièce jointe


GLOBENEWSWIRE (Distribution ID 1001126581)

Nyxoah Annonce ses Prochains Événements Destinés aux Investisseurs

Nyxoah Annonce ses Prochains Événements Destinés aux Investisseurs

Mont–Saint–Guibert, Belgique – 2 septembre 2025, 22h30 CET / 16h30 ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (« Nyxoah » ou la « Société »), une société de technologie médicale développant des alternatives thérapeutiques révolutionnaires pour l'apnée obstructive du sommeil (AOS) par la neuromodulation, a annoncé aujourd'hui qu’elle participera aux événements suivants au cours du mois de septembre :

2025 Wells Fargo Healthcare Conference
3 septembre – Boston, MA

Cantor Global Healthcare Conference 2025
4 septembre – New York, NY
Fireside Chat : 11:30–12:00 pm ET
Webcast : Cantor Fireside Chat Webcast

Morgan Stanley 23rd Annual Global Healthcare Conference
9 septembre – New York, NY
Heure de presentation : 5:35–6:10 pm ET
Webcast: : Morgan Stanley Fireside Chat Webcast

Baird's 2025 Global Healthcare Conference
10 septembre – New York, NY

Une retransmission en direct des événements sera accessible sur le site Web Relations Investisseurs de Nyxoah et pourra être visionnée en différé après les événements. La Société sera également disponible pour des rencontres individuelles avec les investisseurs institutionnels participant aux événements.

A propos de Nyxoah

Nyxoah opère dans le secteur des technologies médicales. Elle se concentre sur le développement et la commercialisation de solutions innovantes destinées à traiter le Syndrome d’Apnées Obstructives du Sommeil (SAOS). La principale solution de Nyxoah est le système Genio®, une thérapie de neurostimulation du nerf hypoglosse sans sonde et sans batterie qui a reçu le marquage CE, centrée sur le patient et destinée à traiter le Syndrome d’Apnées Obstructives du Sommeil (SAOS), le trouble respiratoire du sommeil le plus courant au monde. Ce dernier est associé à un risque accru de mortalité et des comorbidités, dont les maladies cardiovasculaires. La vision de Nyxoah est que les patients souffrant de SAOS doivent pouvoir profiter de nuits réparatrices et vivre pleinement leur vie.

À la suite de la finalisation probante de l’étude BLAST OSA, le système Genio® a reçu le marquage européen CE en 2019. Nyxoah a réalisé avec succès deux IPO : l’une sur Euronext Bruxelles en septembre 2020 et l’autre sur le NASDAQ en juillet 2021. Grâce aux résultats positifs de l'étude BETTER SLEEP, Nyxoah a reçu le marquage CE pour l’extension de ses indications thérapeutiques aux patients souffrant de collapsus concentrique complet (CCC), pour lesquels les thérapies concurrentes sont actuellement contre–indiquées. En outre, la Société a annoncé les résultats positifs de l'étude pivot DREAM IDE et l'approbation par la FDA américaine d'une demande d'autorisation préalable à la mise sur le marché.

Pour plus d’informations, visitez www.nyxoah.com

Attention – Marquage CE depuis 2019. Dispositif de recherche aux États–Unis. Approuvé par la FDA en août 2025 en tant que dispositif disponible uniquement sur prescription médicale.

Déclarations Prospectives

Certaines déclarations, convictions et opinions contenues dans ce communiqué de presse sont de nature prospective et reflètent les attentes actuelles de la Société ou, le cas échéant, de ses administrateurs ou de sa direction concernant le système Genio ; les études cliniques prévues et en cours sur le système Genio ; les avantages potentiels du système Genio ; les objectifs de Nyxoah en matière de développement, de parcours réglementaire et d'utilisation potentielle du système Genio ; la stratégie de commercialisation de la société et son entrée sur le marché américain ; et les résultats d'exploitation, la situation financière, la liquidité, les performances, les perspectives, la croissance et les stratégies de la société. De par leur nature, les déclarations prospectives comportent un certain nombre de risques, d'incertitudes, d'hypothèses et d'autres facteurs qui pourraient faire en sorte que les résultats ou événements réels diffèrent sensiblement de ceux exprimés ou sous–entendus dans les déclarations prospectives. Ces risques, incertitudes, hypothèses et facteurs pourraient avoir une incidence défavorable sur les résultats et les effets financiers des plans et événements décrits dans le présent document. En outre, ces risques et incertitudes comprennent, sans s'y limiter, les risques et incertitudes énoncés dans la section « Facteurs de risque » du rapport annuel de la société sur le formulaire 20–F pour l'exercice clos le 31 décembre 2024, déposé auprès de la Securities and Exchange Commission (« SEC ») le 20 mars 2025, et dans les rapports ultérieurs que la Société dépose auprès de la SEC. Une multitude de facteurs, y compris, mais sans s'y limiter, les changements dans la demande, la concurrence et la technologie, peuvent faire en sorte que les événements, les performances ou les résultats réels diffèrent considérablement de toute évolution prévue. Les déclarations prospectives contenues dans le présent communiqué de presse concernant les tendances ou activités passées ne constituent pas des garanties de performances futures et ne doivent pas être interprétées comme une indication que ces tendances ou activités se poursuivront à l'avenir. En outre, même si les résultats ou développements réels sont conformes aux déclarations prospectives contenues dans le présent communiqué de presse, ces résultats ou développements ne sont pas nécessairement indicatifs des résultats ou développements futurs. Aucune déclaration ni garantie n'est faite quant à l'exactitude ou à l'équité de ces déclarations prospectives. Par conséquent, la Société décline expressément toute obligation ou engagement de publier des mises à jour ou des révisions des déclarations prospectives contenues dans le présent communiqué de presse à la suite d'un changement dans les attentes ou d'un changement dans les événements, les conditions, les hypothèses ou les circonstances sur lesquels ces déclarations prospectives sont fondées, sauf si la loi ou la réglementation l'exige expressément. Ni la Société, ni ses conseillers ou représentants, ni aucune de ses filiales, ni aucun des dirigeants ou employés de ces personnes ne garantissent que les hypothèses sous–jacentes à ces déclarations prospectives sont exemptes d'erreurs, et n'acceptent aucune responsabilité quant à l'exactitude future des déclarations prospectives contenues dans le présent communiqué de presse ou à la réalisation effective des développements prévus. Vous ne devez pas vous fier indûment aux déclarations prospectives, qui ne sont valables qu'à la date du présent communiqué de presse.

Contacts :

Nyxoah
John Landry, CFO
[email protected]

Medias
Aux États–Unis
FINN Partners – Alyssa Paldo
[email protected]

International / Allemagne
MC Services – Anne Hennecke
nyxoah@mc–services.eu

Belgique / France
Backstage Communication – Gunther De Backer
[email protected]

Pièce jointe


GLOBENEWSWIRE (Distribution ID 1001126003)

Nyxoah Announces Upcoming Investor Events

Nyxoah Announces Upcoming Investor Events

Mont–Saint–Guibert, Belgium – September 2, 2025, 10:30pm CET / 4:30PM ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the following events during September:

2025 Wells Fargo Healthcare Conference
September 3rd – Boston, MA

Cantor Global Healthcare Conference 2025
September 4th – New York, NY
Fireside Chat: 11:30–12:00 pm ET
Webcast: Cantor Fireside Chat Webcast

Morgan Stanley 23rd Annual Global Healthcare Conference
September 9th – New York, NY
Presentation Time: 5:35–6:10 pm ET
Webcast: : Morgan Stanley Fireside Chat Webcast

Baird's 2025 Global Healthcare Conference
September 10th – New York, NY

A live webcast of the events can be accessed by visiting Nyxoah’s Investor Relations website and will be available for replay following the events. The Company will also be available for 1×1 meetings with institutional investors attending the events.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient–centered, leadless and battery–free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and U.S. FDA approval of a Premarket Approval application.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. FDA approved in August 2025 as prescription–only device.

FORWARD–LOOKING STATEMENTS

Certain statements, beliefs and opinions in this press release are forward–looking, which reflect the Company’s or, as appropriate, the Company directors’ or managements’ current expectations regarding the Genio system; planned and ongoing clinical studies of the Genio system; the potential advantages of the Genio system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio system; the Company's commercialization strategy and entrance to the U.S. market; and the Company's results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward–looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward–looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20–F for the year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2025, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward–looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward–looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward–looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward–looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward–looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward–looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward–looking statements, which speak only as of the date of this press release.

Contacts:

Nyxoah
John Landry, CFO
[email protected]

For Media
In United States
FINN Partners – Alyssa Paldo
[email protected]

In International/Germany
MC Services – Anne Hennecke
anne.hennecke@mc–services.eu

In Belgium/France
Backstage Communication – Gunther De Backer
[email protected]

Attachment


GLOBENEWSWIRE (Distribution ID 1001126003)